Financial Position and Capital Requirements - The company has approximately $1,479,471 available outside the trust account to fund working capital requirements following the initial public offering [179]. - The company may incur significant costs in pursuit of acquisition plans, and management plans to address capital needs through potential loans from affiliates [177]. - The company has raised gross proceeds of $181,631,250 from its initial public offering and private placement, which includes $7,000,000 of deferred underwriting commissions held in the trust account [208]. - The company may need to seek additional financing if the net proceeds from its initial public offering are insufficient for the initial business combination [219]. - The company may incur substantial debt to complete a business combination, which could adversely affect its financial condition and shareholder value [207]. - The company is subject to risks associated with cross-border business combinations, including regulatory approvals and currency fluctuations [301]. - The company has no operating history and no revenues, making it difficult to evaluate its ability to achieve its business objectives [321]. Trust Account and Redemption Risks - If the initial business combination is not completed within the required time period, public shareholders may receive only about $10.05 per share upon liquidation of the trust account [178]. - The trust account funds will be invested in U.S. government treasury obligations or held in cash, with a risk of negative interest rates impacting the per-share redemption amount [181]. - Public shareholders may receive approximately $10.05 per share or less upon liquidation of the trust account if the initial business combination is not completed [194]. - The trust account may not protect funds from third-party claims, potentially reducing the per-share redemption amount below $10.05 [236]. - The trust account may be reduced below $10.05 per public share if Sponsor HoldCo does not enforce indemnification obligations, impacting funds available for distribution to public shareholders [239]. - If the initial business combination does not meet the company's general criteria and guidelines, it may lead to increased shareholder redemptions and difficulties in closing the transaction [200]. Regulatory and Compliance Issues - If deemed an investment company under the Investment Company Act, the company may face burdensome compliance requirements that could hinder the completion of the initial business combination [187]. - The company must ensure that investment securities do not exceed 40% of total assets to avoid being classified as an investment company [189]. - Compliance with the Sarbanes-Oxley Act may increase the time and costs necessary to complete the initial business combination [224]. - The company is classified as a "blank check" company under U.S. securities laws, with net tangible assets of at least $5,000,001, exempting it from certain SEC investor protections [324]. - The SEC adopted new rules for SPACs on January 24, 2024, requiring additional disclosures related to business combinations, dilution, and conflicts of interest [326]. - The company may be subject to a 1% U.S. federal excise tax on stock buybacks if it becomes a "covered corporation" in the future, which could impact cash available for redemptions [331]. Management and Operational Risks - The company may face challenges in assessing the management capabilities of target businesses, potentially impacting post-combination operations [204]. - The departure of key personnel from a target business upon completion of the initial business combination could negatively impact operations and profitability [206]. - The company is dependent on a small group of key personnel, including the CEO and CFO, whose unexpected departure could adversely affect operations [269]. - The success of the initial business combination is contingent upon the efforts of key personnel, and the loss of these individuals could negatively impact profitability [271]. - Conflicts of interest may arise as directors and officers allocate their time to other businesses, potentially impacting the ability to complete an initial business combination [268]. - The management team and board of directors have significant experience but may become involved in litigation that could divert attention from the initial business combination [283]. Shareholder Rights and Interests - The company is not required to obtain an independent fairness opinion for its business combination, which may leave shareholders without assurance regarding the fairness of the transaction price [202]. - The absence of a specified maximum redemption threshold allows the company to complete a business combination even if a substantial majority of shareholders disagree [214]. - Shareholders holding over 15% of Class A ordinary shares may lose the ability to redeem shares in excess of that amount without prior consent [235]. - The company may issue additional Class A ordinary shares or preference shares to complete the initial business combination, which could dilute existing shareholders' interests [248]. - Holders of founder shares will control the appointment of the board of directors until the initial business combination is completed, potentially limiting influence from public shareholders [250]. - The staggered board structure may prevent the appointment of new directors prior to the initial business combination, allowing significant influence from holders of founder shares [252]. Market and Economic Conditions - Adverse developments in the financial services industry could negatively impact the company's financial condition and results of operations [186]. - Economic conditions in the operating country could adversely affect the company's ability to find attractive target businesses for the initial business combination [225]. - Risks associated with acquiring businesses in foreign countries may impact operations negatively [300]. - Exchange rate fluctuations may adversely affect the company's net assets and distributions if it acquires a non-U.S. target [309]. Legal and Tax Implications - If bankruptcy proceedings occur after distributing trust account proceeds, shareholders may face claims for recovery of amounts received [183]. - The company may face uncertain U.S. federal income tax consequences related to the allocation of purchase price between shares and warrants [233]. - The company's PFIC status could result in adverse U.S. federal income tax consequences for U.S. investors, depending on various factors related to business combinations [330]. - The company may reincorporate in another jurisdiction, which could result in tax liabilities for shareholders and affect the enforcement of legal rights [304][306]. Warrant and Share Structure - The company has the ability to redeem outstanding public warrants at a price of $0.01 per warrant if the last reported sale price of Class A ordinary shares equals or exceeds $18.00 per share for any 20 trading days within a 30 trading-day period [261]. - Public warrants are issued to purchase 8,750,000 Class A ordinary shares at a price of $11.50 per share, with private placement warrants also exercisable at the same price [263]. - The company may require holders of public warrants to exercise on a cashless basis, resulting in fewer Class A ordinary shares received upon exercise compared to cash exercises [262]. - The structure of the units, containing one-half of one redeemable public warrant, may result in the units being worth less than those of other blank check companies that include a whole public warrant [265]. - The company may face challenges in consummating an initial business combination due to provisions in the warrant agreement that adjust exercise prices and redemption triggers [267]. - The company may amend the terms of the public warrants with the approval of at least 50% of the then outstanding public warrants, potentially in a manner adverse to holders [256].

Financial Position and Trust Account - The company has approximately $1,479,471 available outside the trust account to fund working capital requirements following the initial public offering [179]. - The trust account funds will be invested in U.S. government treasury obligations or held in cash, with a risk of negative interest rates impacting the per-share redemption amount [181]. - Public shareholders may receive approximately $10.05 per share, or less in certain circumstances, upon liquidation of the trust account [194]. - The trust account may be reduced below $10.05 per public share if Sponsor HoldCo does not enforce indemnification obligations, impacting funds available for distribution to public shareholders [239]. - The gross proceeds from the initial public offering and the sale of private placement units and restricted Class A shares amounted to $181,631,250, which includes $7,000,000 of deferred underwriting commissions held in the trust account [208]. - If the initial business combination is not completed, public shareholders may receive approximately $10.05 per share from the trust account, or less in certain circumstances [178]. - The company must ensure net tangible assets are at least $5,000,001 after redemptions to consummate its initial business combination [214]. - The company may face challenges in completing a business combination with a target that does not meet its general criteria and guidelines, potentially leading to shareholder redemption [200]. - The company may incur significant costs in pursuing acquisition plans, and additional capital may be required from affiliates or third parties [179]. - The company may incur substantial debt to complete a business combination, which could negatively impact the value of shareholders' investments [207]. Business Combination Risks - The company may seek business combination opportunities with early-stage or financially unstable businesses, which carry inherent risks [201]. - The management's ability to assess the capabilities of a target's management may be limited, potentially impacting the success of the business combination [204]. - If the initial business combination is not completed within the required time period, public shareholders may only receive their pro rata portion of the funds in the trust account [203]. - The company may face challenges in completing its initial business combination with multiple target businesses due to complex accounting issues and the need for pro forma financial statements [209]. - The company may attempt to complete its initial business combination with a private company, which could result in lower profitability than expected due to limited available information [213]. - The company may face increased tax obligations and complexities due to potential business combinations with target companies in multiple jurisdictions [222]. - The company may not maintain control of a target business after the initial business combination, potentially affecting operations [298]. - The company may face significant costs in pursuing its acquisition plans, which could impact its financial stability [322]. - The company is subject to risks associated with cross-border business combinations, including regulatory approvals and currency fluctuations [301]. - Risks associated with acquiring businesses in foreign countries may impact operations negatively [300]. Regulatory and Compliance Issues - If deemed an investment company under the Investment Company Act, the company may face burdensome compliance requirements and restrictions on operations [187]. - The company does not plan to engage in activities that would classify it as an investment company, focusing instead on completing an initial business combination [189]. - Compliance with the Sarbanes-Oxley Act may increase the time and costs necessary to complete the initial business combination [224]. - The company is classified as a "blank check" company under U.S. securities laws, with net tangible assets of at least $5,000,001, exempting it from certain SEC investor protections [324]. - The SEC adopted new rules for SPACs on January 24, 2024, requiring additional disclosures related to business combinations, dilution, and conflicts of interest [326]. - Changes in laws or regulations could adversely affect the company's ability to complete its initial business combination and its overall operations [325]. - The company may be treated as a Passive Foreign Investment Company (PFIC), which could result in adverse U.S. federal income tax consequences for U.S. investors [330]. Shareholder Considerations - The company may issue additional Class A ordinary shares or preference shares to complete the initial business combination, which could dilute existing shareholders' interests [248]. - Holders of founder shares will control the appointment of the board of directors until the initial business combination is completed, potentially influencing shareholder votes [250]. - The staggered board structure may limit the ability of public shareholders to influence director appointments prior to the initial business combination [252]. - Shareholders may be liable for claims against the company if distributions are made while the company is unable to pay its debts, potentially leading to recovery actions by a liquidator [242]. - The company may seek shareholder approval to extend the 24-month period for completing the initial business combination, offering public shareholders the right to redeem their shares for a pro rata share of the trust account [241]. - The company has not registered Class A ordinary shares issuable upon exercise of warrants, which may limit the ability of investors to exercise their warrants and could result in them expiring worthless [243]. - The existence of registration rights for initial shareholders may complicate the completion of the initial business combination and adversely affect the market price of Class A ordinary shares [246]. - The company may significantly dilute the equity interest of investors in its initial public offering, which could increase if anti-dilution provisions result in the issuance of Class A ordinary shares on a greater than one-to-one basis upon conversion of Class B ordinary shares [254]. - The company may issue shares at a price significantly lower than the market price during private placement transactions (PIPE transactions) related to the initial business combination [226]. - The company may require holders of public warrants to exercise on a cashless basis, resulting in fewer Class A ordinary shares received upon exercise compared to cash exercises [262]. Management and Operational Risks - The company is dependent on the performance of a single business or asset, increasing its vulnerability to economic and competitive risks [211]. - The company is dependent on a small group of key personnel, including the CEO and CFO, whose unexpected departure could adversely affect operations [269]. - The success of the initial business combination is contingent upon the efforts of key personnel, and the loss of these individuals could negatively impact post-combination operations and profitability [271]. - Conflicts of interest may arise as directors and officers allocate their time to other businesses, potentially impacting the ability to complete the initial business combination [268]. - The management team and board of directors have significant experience but may become involved in litigation or investigations that could divert attention from the initial business combination [283]. - The letter agreement with the sponsor and directors can be amended without shareholder approval, which may adversely affect the value of investments [284]. - If the initial business combination is not completed, the sponsor and directors will lose their entire investment, creating potential conflicts in determining appropriate business combination targets [285]. Market and Economic Conditions - Adverse developments in the financial services industry could negatively impact the company's financial condition and results of operations [186]. - Economic conditions in the operating country could lead to decreased demand for spending, adversely affecting the ability to find attractive target businesses [225]. - The company’s operations and financial results may be significantly affected by the economic and political conditions in the country of the target business [310]. - The company may face challenges in enforcing legal rights in the U.S. due to its incorporation in the Cayman Islands [311]. - Management's unfamiliarity with U.S. securities laws post-business combination could lead to regulatory issues [319]. - Cyber incidents or attacks could lead to information theft and financial loss, as the company lacks significant investments in data security protection [327].

Financial Performance - For the year ended December 31, 2025, the company reported a net income of $5,055,742, primarily from investment income of $6,079,742 [294]. - Cash used in operating activities for the year ended December 31, 2025, was $991,948 [298]. - The company has not generated any revenues to date and does not expect to until after completing its initial business combination [293]. Capital Raising - Renatus Tactical Acquisition Corp I completed its initial public offering of 24,150,000 Units at a price of $10.00 per Unit, generating gross proceeds of $241,500,000 [290]. - The private placement of 3,821,591 warrants at $1.00 per warrant generated additional gross proceeds of $3,821,591 [290]. - Total cash provided by financing activities for the year ended December 31, 2025, was $243,104,269, from the initial public offering and private placement [299]. - The company incurred transaction costs of $12,213,743 related to the initial public offering [297]. - The underwriters received a cash underwriting discount of $1,207,500 and a deferred fee of up to $8,452,500 [306]. Cash Position - As of December 31, 2025, the trust account held cash of $248,183,492, intended for the initial business combination [300]. - As of December 31, 2025, the company had cash of $4,031 in its operating bank account for operational expenses [301].

Initial Public Offering - Renatus Tactical Acquisition Corp I completed its initial public offering of 24,150,000 Units at a price of $10.00 per Unit, generating gross proceeds of $241,500,000[290]. - A total of $242,103,750 of the net proceeds from the initial public offering and private placement was placed in a trust account[291]. - The company incurred $12,213,743 in transaction costs related to the initial public offering[297]. - The underwriters received a cash underwriting discount of $1,207,500 and are entitled to a deferred fee of up to $8,452,500[306]. Financial Performance - For the year ended December 31, 2025, the company reported a net income of $5,055,742, primarily from investment income of $6,079,742[294]. - Cash used in operating activities for the year ended December 31, 2025, was $991,948[298]. - Cash provided by financing activities for the year ended December 31, 2025, was $243,104,269, from the initial public offering and private placement[299]. - As of December 31, 2025, cash held in the trust account amounted to $248,183,492, intended for the initial business combination[300]. - The company has not generated any operating revenues to date and does not expect to do so until after completing its initial business combination[293]. Debt and Financing - The company has no long-term debt or off-balance sheet financing arrangements as of December 31, 2025[304].

Financial Performance - Net income for Q4 2025 was $80.8 million, or $1.60 per share, compared to $77.2 million, or $1.54 per share in Q4 2024, representing a 4.7% increase in net income year-over-year [5]. - For the fiscal year 2025, net income was $209.7 million, or $4.17 per share, up from $195.5 million, or $3.92 per share in fiscal year 2024, marking a 7.2% increase in net income [5]. - Gross profit for Q4 2025 was $209.97 million, compared to $199.49 million in Q4 2024, reflecting a 5.9% increase [10]. Sales Performance - Net sales for the 13-week fiscal quarter increased by 5.3% to $399.1 million from $379.2 million in the prior year [3]. - Comparable store net sales for the same period rose by 3.9% compared to the previous year [3]. - Total net sales for the 52-week fiscal year increased by 6.6% to $1.298 billion from $1.218 billion in the prior year [4]. - Online sales for the fiscal year rose by 9.8% to $217.1 million compared to $197.7 million in the previous year [4]. Operational Metrics - The company operated 440 retail stores in 42 states at the end of fiscal year 2025, a slight decrease from 441 stores in the previous year [7]. - Total assets as of January 31, 2026, were $991.3 million, up from $913.2 million at the end of the previous fiscal year [11]. - Total stockholders' equity increased to $424.6 million from $423.8 million year-over-year [11].

Corporate Structure and Operations - The Corporation operates through its wholly-owned subsidiary, Meridian Bank, providing a range of banking services across Pennsylvania, New Jersey, Delaware, Central Maryland, and southwest Florida [22]. - Meridian currently operates four wholly-owned subsidiaries, including a registered investment advisory firm and a real estate holding company [55]. - The Corporation's principal source of cash flow is dividends from its subsidiaries, which are subject to limitations under Pennsylvania law [62]. - The Bank employs 327 individuals, with a turnover rate of approximately 1.9%, indicating a high retention rate compared to peers [42]. Financial Performance - Consolidated net income rose by $5.5 million, or 33.6%, to $21.8 million for the year ended December 31, 2025 [214]. - Basic earnings per share rose to $1.93 in 2025 from $1.47 in 2024 [213]. - Diluted earnings per share increased to $1.89 in 2025 from $1.45 in 2024 [213]. - The net interest margin improved to 3.64% from 3.16% year-over-year [217]. - Net interest income increased by $16.7 million, or 23.5%, due to a higher volume of earning assets [214]. - Non-interest income decreased by $2.2 million, or 5.2%, primarily due to a decline in MSR sales [214]. Market and Economic Environment - The median household income in the Philadelphia metropolitan area is $101,000, while the Baltimore metropolitan area is $116,000, both above the national average of $82,000 [33]. - The current economic environment features moderate interest rates following three rate cuts by the Fed in 2025, impacting the company's ability to attract deposits and generate earnings [118]. - The Bank faces substantial competition from local, regional, and national financial institutions, as well as non-bank fintech companies [36]. Regulatory Environment - Meridian Corporation is subject to extensive regulation under federal and state banking laws, which may materially affect growth potential and financial performance [49]. - The Bank is an FDIC-insured commercial bank chartered in Pennsylvania, with regulatory oversight from the FDIC and the Pennsylvania Department of Banking and Securities [50]. - The minimum Basel III regulatory capital requirements include 4.5% CET1 to risk-weighted assets and a 2.5% capital conservation buffer, resulting in effective minimum ratios of 7% CET1 [70][71]. - The Community Bank Leverage Ratio (CBLR) framework requires a leverage ratio greater than 9%, with proposals to lower this threshold to greater than 8% [73]. Risk Management - The Corporation maintains numerous internal controls to ensure safety and soundness, including policies related to lending, compliance, and risk management [50]. - The financial institution faces risks from fraudulent activities and cybersecurity incidents, which could lead to financial losses and damage to reputation [133]. - The company must manage risks while increasing loans and deposits, adhering to prudent underwriting standards, and maintaining adequate capital [132]. Asset Management and Investments - As of December 31, 2025, the company owned $226 million in investment securities, primarily in U.S. government and agency obligations, which have seen significant declines in trading value due to inflationary pressures and interest rate increases [120]. - The corporation's real estate loans included $879.4 million of commercial real estate loans (39.9% of total portfolio loans) and $330.5 million of construction and development loans (15.0% of total portfolio loans) as of December 31, 2025 [173]. - The corporation's residential mortgage loans amounted to $236.1 million, and home equity loans were $107.0 million, representing 15.6% of total portfolio loans [173]. Community Engagement - The Corporation donated $727,000 to over 100 organizations in 2025, emphasizing its commitment to community support [40]. - The Bank received a "Satisfactory" rating in its most recent Community Reinvestment Act examination in 2023 [101]. Technology and Innovation - The corporation has invested in IT security, enhancing defenses and training to address cybersecurity risks [191]. - Rapid technological changes in the financial services industry require the company to effectively embrace new technologies to remain competitive [140]. - The evolving regulatory framework around artificial intelligence (AI) may impact the company's operations and compliance costs [141]. Future Outlook and Strategy - The company evaluates opportunities for acquisitions, which could materially affect its operating results and financial condition, including potential dilution of current shareholders' ownership [123]. - The company's growth strategy focuses on organic growth supplemented by opportunistic acquisitions, but there is no assurance of continued profitability or consistent earnings [131]. - The company may need to raise additional capital in the future, which could be challenging if market conditions are unfavorable, potentially affecting liquidity and financial condition [130].

Company Performance - Haleon has demonstrated solid progress over the past year, indicating resilience and long-term potential[10] Annual General Meeting (AGM) Details - The 2026 Annual General Meeting (AGM) will be held virtually on April 29, 2026, at 3:00 PM (BST)[11] - The Board has proposed 23 resolutions for shareholder consideration during the AGM[13] - Shareholders are encouraged to submit questions in advance via the Lumi platform starting from March 13, 2026[17] - Voting will be conducted via a poll during the AGM, with results published on the company's website shortly after[16] - The AGM aims to facilitate global shareholder engagement while reducing the environmental footprint[12] - The company emphasizes the importance of shareholder participation in the AGM[12] - The Chair expresses gratitude for ongoing trust and support from shareholders[18] - The deadline for submitting proxy votes is 3.00pm (BST) on Monday 27 April 2026[105] - Registered holders of American Depositary Shares (ADS) must submit voting instructions by 8.00am (EDT) on Friday 24 April 2026[112] - Shareholders are encouraged to monitor the company's website for any changes to AGM arrangements[116] Board of Directors - A new Non-Executive Director, Matthew Shattock, has joined the Board, bringing extensive leadership experience in the consumer goods sector[14] - All Directors are standing for election or re-election in accordance with the UK Corporate Governance Code[15] - The company emphasizes the importance of maintaining an appropriate balance of skills and experience among its Directors for effective governance[66] - The company has engaged with shareholders regarding proposed changes to the Directors' Remuneration Policy, ensuring alignment with strategic ambitions[58] - The Directors' Remuneration Report for the year ended 31 December 2025 is to be presented at the AGM, detailing the remuneration of the Directors[57] Financial Proposals - The company plans to declare a final dividend of 4.9 pence per ordinary share for the year ended 31 December 2025, pending shareholder approval[61] - The company is seeking approval for the Directors' Remuneration Policy, which has been supported by shareholders and reflects current market conditions[58] - KPMG LLP is recommended for reappointment as the external auditor for the financial year ending 31 December 2026, following a satisfactory performance in the previous audit[68] - The company aims to authorize political donations and expenditures not exceeding £100,000 during the specified period, although it maintains a policy against making political donations[74] - The company seeks authority to allot shares up to an aggregate nominal amount of £29.69 million, representing approximately 2.97 billion ordinary shares[79] - The proposed share allotment authority is equivalent to approximately 33% of the issued share capital of the company, excluding treasury shares[77] - The Directors are authorized to allot equity securities for cash up to an aggregate nominal amount of £8,900,000, representing 890,000,000 ordinary shares[91] - The authority to allot additional equity securities is limited to 20% of the nominal amount of the initial allotment, specifically for follow-on offers[80] - The Company intends to buy back £500 million worth of shares during the financial year ending December 31, 2026[96] - The maximum number of ordinary shares that may be purchased is 890,000,000, approximately 10% of the issued ordinary share capital[97] - The minimum price for purchasing shares is the nominal value, while the maximum price is set at 5% above the average market quotation for the five business days preceding the purchase[97] - The authority for market purchases of shares will expire at the conclusion of the 2027 AGM or on June 30, 2027, whichever is earlier[90] Shareholder Information - The company confirms that it will provide electronic voting options for shareholders participating in the AGM[98] - The company provides extensive information and services through its Registrar, Equiniti[133] - The company's issued share capital consists of 8,952,353,648 ordinary shares of £0.01 each, with total voting rights amounting to 8,908,584,852[122] - The total number of non-voting preference shares is 25,000,000, which do not carry voting rights[122] - The company holds 43,768,796 ordinary shares as treasury shares[122] - Voting will be conducted by a poll, ensuring transparency as votes are counted based on the number of shares held[114] - The company may process personal data of participants at the AGM, including webcasts and recordings[129] - Shareholders are advised to be cautious of investment scams and unsolicited communications[130] Company Information - Haleon plc will hold its Annual General Meeting on April 29, 2026, at 3:00 PM (BST)[136] - The company is incorporated in England and Wales with a registered number of 13691224[140] - The registered office of Haleon is located at Building 5, First Floor, The Heights, Weybridge, Surrey, England, KT13 0NY[140] - The Executive Directors of Haleon are Brian McNamara and Dawn Allen[140] - The company has a diverse Board of Directors, including both Executive and Non-Executive Directors[140] - Ordinary shares of Haleon are valued at £0.01 each[140] - The company utilizes a paperless settlement system for securities trades operated by Euroclear UK & Ireland Limited[140] - J.P. Morgan Chase Bank, N.A. serves as the Depositary for Haleon[140] - Shareholders can find their reference number on share certificates or by contacting Haleon's Registrar, Equiniti[140] - The company is committed to sustainability, using 100% offshore wind electricity for its publication[139]

Financial Performance - XBiotech generated a total of $750 million in income from the sale of its True Human™ antibody Bermekimab between December 30, 2019, and June 30, 2021[26]. - The company has returned a total of $495 million to shareholders through stock repurchase and dividends since 2020[26]. - The company has incurred significant losses since its inception and may continue to do so, with a net loss reported for the fiscal year ending December 31, 2025[49]. - The company has not generated any revenue from product sales to date and may never sustain profitability[54]. - The company completed a modified Dutch auction tender offer for its common shares in June 2023, consuming $14 thousand of cash resources[52]. - As of December 31, 2025, the accumulated deficit for XBiotech was $136.3 million, with a net loss of $45.5 million for the year, compared to a net loss of $38.5 million for the previous year[154]. - The company does not expect to generate any revenue during the fiscal year of 2026 and anticipates significant and increasing operating losses as it advances drug candidates through testing[154]. - The company reported total liabilities of $9.7 million as of December 31, 2025, down from $16.8 million in 2024, representing a decrease of 42.0%[198]. - Shareholders' equity decreased to $140.4 million in 2025 from $182.3 million in 2024, a decline of 23.0%[198]. Research and Development - XBiotech is developing two anti-IL-1a product candidates in parallel, targeting oncology, rheumatology, and neurology, following the sale of its previous IL-1a antibody[25]. - A clinical study for the Natrunix™ True Human™ antibody targeting IL-1a in pancreatic cancer included 60 subjects and showed promising results in safety and efficacy[29]. - The company launched a clinical Rheumatology program in August 2023, enrolling 233 subjects to investigate Natrunix's efficacy for rheumatoid arthritis[30]. - XBiotech completed a Phase I study for its True Human™ antibody Hutrukin, demonstrating safety and tolerability for reducing brain injury after stroke[31]. - Research and development expenses for the year ended December 31, 2025, amounted to approximately $47.4 million[51]. - Research and development expenses increased by 26% to $47.4 million for the year ended December 31, 2025, compared to $37.8 million for the year ended December 31, 2024[174]. - Salaries and related expenses within research and development rose by 90% to $34.4 million for the year ended December 31, 2025, from $18.1 million in 2024[173]. - The company recorded a total of $397.1 million in research and development expenses from inception through December 31, 2025[158]. - The company anticipates that clinical development costs may further increase with more advanced studies in the future[157]. Regulatory and Market Challenges - The ability to commercialize products successfully depends on obtaining regulatory approvals, which typically takes years and is not guaranteed[59]. - The company has no products that have gained regulatory approval, making its financial operations heavily reliant on future approvals[59]. - The regulatory approval process by the FDA typically takes several years and is unpredictable, with no current approvals for any product candidates[67]. - Factors leading to potential failure in receiving marketing approval include disagreements over clinical trial design and insufficient data[68]. - Additional information may be required by regulatory authorities, potentially delaying approval and commercialization plans[69]. - Undesirable side effects could lead to halted clinical trials and restrict the commercial profile of approved products[71]. - Regulatory authorities may impose ongoing requirements and monitoring even after approval, affecting marketing and distribution[74]. - Coverage and adequate reimbursement from third-party payers are critical for successful commercialization of products[84]. - Delays in obtaining coverage and reimbursement for newly approved drugs could adversely impact financial results[85]. - Regulatory approval in foreign jurisdictions is necessary for market access, with varying requirements and potential delays[82]. - Non-compliance with regulatory requirements could lead to severe penalties, impacting the ability to commercialize products[78]. Competition and Market Position - The company faces substantial competition from larger pharmaceutical and biotechnology companies, which may limit its ability to develop or commercialize product candidates[92]. - The company may struggle to achieve market acceptance for its product candidates, which is critical for commercial success[88]. - The company may not receive adequate reimbursement from third-party payers for its product candidates, impacting their market viability[89]. - The company’s research programs may not succeed, and there are multiple risks associated with drug development that could impede progress[90]. - The company may face difficulties in managing growth and expanding operations effectively, which could hinder its ability to achieve strategic objectives[99]. Intellectual Property and Governance - The company relies on its ability to protect intellectual property rights, which is crucial for maintaining its competitive position in the biotechnology and pharmaceutical sectors[110]. - There is uncertainty regarding the issuance and enforceability of pending patent applications, which may limit the company's ability to protect its technologies and products[112]. - The company has substantial control concentrated among directors and principal shareholders, owning approximately 27.0% of outstanding common stock, which could affect corporate governance and market price[122]. - The company may face significant costs and operational disruptions if it infringes on third-party intellectual property rights, which could require licensing or redesigning products[115]. - The company is governed by British Columbia corporate laws, which may affect shareholder rights differently compared to Delaware laws, potentially impacting stock attractiveness[130]. Operational and Financial Management - The company has identified several major areas of unmet medical need for its infectious disease pipeline, including therapies for MRSA and C. difficile[32][34]. - The company expanded its manufacturing and R&D center in 2022, enhancing its capacity for drug production and research activities[36]. - The company has 85 employees as of December 31, 2025, and anticipates needing additional personnel to support future growth and operations[97]. - The company manufactured Bermekimab under a clinical manufacturing agreement with Janssen, which provided fixed payments through 2021, but the contract terminated in November 2022[155]. - The company entered into a convertible loan agreement providing $10 million for the construction of a new research and development facility, which was fully repaid by January 31, 2025[182]. - The company does not engage in off-balance sheet activities, including structured finance or special purpose entities[185]. - The company has a cash and cash equivalents balance of $125.6 million as of December 31, 2025, which is expected to support major clinical study milestones for at least the next 12 months[214]. - The stock price may be volatile due to various factors, including clinical trial results and market conditions, which could lead to securities class action lawsuits[119]. - The company has implemented cybersecurity measures to protect its information assets, although risks remain due to increasing electronic transactions and reliance on external vendors[139].

Employment and Workforce - As of December 31, 2025, Stagwell employed approximately 10,951 full-time employees and 1,678 contractors and part-time employees[63]. - Stagwell operates in more than 34 countries and has expanded its global footprint to support clients worldwide[62]. - Stagwell's human capital management strategies focus on competitive benefits, talent retention, and employee engagement[65]. - The company has launched various professional development programs, including the Next Dimension experiential learning program and a Global Mentor Program[71]. - Stagwell's corporate culture emphasizes collaboration, inclusivity, and access to high-quality education and resources[74]. - Regular communication, including quarterly global town halls, is a focus to ensure employee engagement and alignment with organizational goals[75]. Financial Performance and Risks - The primary source of revenue comes from agency arrangements, including fees for services, commissions, and performance incentives[62]. - A 10% increase or decrease in interest rates would change Stagwell's annual interest expense by $2.9 million[331]. - Stagwell's debt obligations include amounts outstanding under its Credit Agreement and 5.625% Notes, with interest rates based on SOFR, EURIBOR, and SONIA[330]. - The company is exposed to foreign exchange risks due to operations in multiple currencies, primarily transacting in U.S. dollars, Canadian dollars, Euros, and British Pounds[332].

Ownership and Properties - As of February 1, 2026, the Partnership owned a 40-50% interest in 7 residential and mixed-use complexes, totaling 688 residential units and one commercial unit[17]. - The Partnership completed property improvements in 2025 at a total cost of approximately $30,691,000, with plans to invest approximately $17,069,000 in capital improvements for all properties in 2026[33]. - The Partnership purchased a mixed-use property in Belmont, Massachusetts for $172,000,000, financed through a $40,000,000 borrowing on the Master Credit Facility and a $67,500,000 interim mortgage loan[32]. Financial Performance - In 2025, the Partnership paid an aggregate distribution of $144.00 per Unit, totaling $16,793,527, compared to $84.00 per Unit in 2024, totaling $11,244,559[20]. - The Partnership's line of credit agreement includes a $25,000,000 revolving line with a floating interest rate, and as of December 31, 2025, the Partnership was in compliance with financial covenants[36]. Debt and Financing - As of December 31, 2025, the Partnership had approximately $705,827,000 in long-term debt, all requiring fixed interest payments[218]. - The Partnership's Master Credit Facility Agreement includes an initial advance of $156,000,000 at a fixed interest rate of 2.97%, maturing on December 31, 2031[25]. Share Repurchase - The Partnership has repurchased 1,559,409 Depositary Receipts at an average price of $32.06 per receipt, totaling approximately $56,911,000 since August 20, 2007[23]. Risk Management - The Partnership's market risk primarily involves interest rate risk, with no variable rate debt as of December 31, 2025[217]. - The Partnership's Advisory Committee reviews proposed acquisitions and investments, but has no binding power except for certain approvals[38].